Trial intelligence / Profile preview

Pyrotinib + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel as neoadjuvant therapy for HER2-positive breast cancer

CTR20180941Phase 3Completed

Sponsor

Hengrui Therapeutics

Start

Jun 2018

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1